Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsDividends payablesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PharmaCyte Biotech (PMCB) Short term Debt (2020 - 2021)

PharmaCyte Biotech (PMCB) has disclosed Short term Debt for 6 consecutive years, with $66753.0 as the latest value for Q1 2021.

  • On a quarterly basis, Short term Debt changed N/A to $66753.0 in Q1 2021 year-over-year; TTM through Jan 2021 was $66753.0, a N/A change, with the full-year FY2020 number at $28918.0, changed N/A from a year prior.
  • Short term Debt was $66753.0 for Q1 2021 at PharmaCyte Biotech, up from $54110.0 in the prior quarter.
  • In the past five years, Short term Debt ranged from a high of $66753.0 in Q1 2021 to a low of $28918.0 in Q2 2020.